Robot maker · registered

CMR Surgical

Corporate marketmedicalCurated record

Modular, portable collaborative surgical robotic system whose independent bedside units each provide 7 degrees-of-freedom wristed articulation that mimics human arm movement for minimally invasive surgery; no OR infrastructure modification required. Versius Plus adds Vision for Versius enhanced imaging and AI-assisted haptic guidance. The digital ecosystem (clinical registry + procedure analytics) enables outcomes benchmarking across the install base. Not a fully autonomous system; the surgeon retains direct control; but the platform is software-defined and continuously updated over-the-air.

HeadquartersCambridge, GB

Founded2014

Corporate funding$1.4B

Team501-1000

Deployments4

Open roles0

Company overview

Identity and operating footprint

Company typeRobot maker

Market segmentCorporate

StageSeries D

FoundersMartin Frost, Luke Hares, Mark Slack, Paul Roberts

Regions servedEurope, North America, Asia Pacific, Latin America

Countries deployedGB, IN, IT, FR, DE, GR, ID, BR, AU, US

Service footprintHQ at Evolution Business Park, Cambridge, UK; manufacturing hub in Ely, Cambridgeshire; US commercial operations launched 2026 with Versius Plus following FDA 510(k) clearance

Last reviewed2026-07-05

LinkedInView profile

Robot models

Specifications remain vendor-claimed

Machinemedical

Versius

7 degrees of freedom wristed instrument tip with 360-degree rotational freedom
vendor-stated articulation of the instrument inside the patient body
Claim source
Up to 4 independent bedside units (3 instrument arms + 1 vision arm)
vendor-stated maximum arm configuration per procedure
Claim source

Machinemedical

Versius Plus

FDA 510(k) cleared for cholecystectomy (gallbladder removal), with Vision for Versius enhanced imaging
regulatory clearance status for US commercial use and next-generation imaging capability
Claim source

Deployment log

Announced and cited only

Announced	Customer	Site	Country	Count	Evidence
2026-03-26	US hospital network (commercial debut)	US hospital surgical departments	US	Not disclosed	Announcement
2022-11-29	Ethicon (Johnson & Johnson MedTech), distribution to select hospitals in Italy, France, Germany and Brazil	hospital surgical departments via commercial distribution agreement	IT	Not disclosed	Announcement
2022-09-01	Institut Curie (France)	cancer center / robotic surgery clinical study	FR	Not disclosed	Announcement
2021-07-01	NHS UK hospital network (including Gloucestershire Royal Hospital, West Hertfordshire Teaching Hospitals NHS Trust, East and North Hertfordshire NHS Trust)	NHS hospital surgical departments	GB	Not disclosed	Announcement

Funding history

Publicly announced rounds

2025-04-02$200M

Growth

Ally Bridge Group, Lightrock, SoftBank Group, Trinity Capital

Round source

2023-09-20$165M

Series D

Ally Bridge Group, Cambridge Innovation Capital, Lightrock, SoftBank Group, Tencent

Round source

2021-06-28$600M

Series D

Ally Bridge Group, Cambridge Innovation Capital, Chimera, Chimera Capital, GE Healthcare, LGT, LGT Capital Partners, Lightrock, PFM Health Sciences, RPMI Railpen, SoftBank Vision Fund 2, Tencent, Watrium

Round source

2019-09-17$240M

Series C

Cambridge Innovation Capital, Escala Capital, LGT, Lightrock, Watrium, Zhejiang Silk Road Fund

Round source

2018-06-04$100M

Series B

Cambridge Innovation Capital, Escala Capital, LGT, Watrium, Zhejiang Silk Road Fund

Round source

2017-09-18$26M

Series A

Cambridge Innovation Capital, Escala Capital, Watrium

Round source

2016-07-18$20M

Series A

ABB Technology Ventures, Cambridge Innovation Capital, Escala Capital, LGT Global Invest

Round source

Investors on recordEscala CapitalSoftBank Vision Fund 2SoftBank GroupAlly Bridge GroupChimera CapitalImage Frame InvestmentRailpenTrinity Capital

Company timeline

Milestones and announcements

2026-04-29Submitted 510(k) application to FDA to expand Versius Plus into gynecology (benign total hysterectomy, oophorectomy, salpingectomy, and other gynecologic procedures)GlobeNewswire

2026-04-29CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus into Gynecology ↗GlobeNewswire

2026-03-26Announced 45,000 patients treated globally (40,000+ outside US); made formal US commercial debut with Versius Plus at SAGES 2026 Annual Meeting in TampaCMR Surgical

2026-03-26CMR Surgical Announces 45,000 Patients Treated Globally as Robotic-Assisted Surgery Company Makes Its U.S. Debut ↗GlobeNewswire

2025-12-01Received FDA 510(k) clearance for Versius Plus for cholecystectomy in adult patients ≥22 years; US commercial launch targeted for 2026MedTech Dive

2025-12-01CMR Surgical gains FDA clearance for next-gen Versius Plus surgical robot in cholecystectomy ↗MedTech Dive

2025-04-02Secured $200M+ in combined equity and debt financing (existing investors plus Trinity Capital) to accelerate US commercial launch and global growthGlobeNewswire

2025-04-02CMR Surgical secures more than $200M to accelerate growth ↗GlobeNewswire

2024-10-01Received FDA de novo marketing authorization for Versius Surgical System for general surgery (cholecystectomy): first multi-port soft-tissue surgical robot cleared via FDA de novo pathwayMedTech Dive

2024-10-01CMR Surgical gets FDA de novo nod for Versius robot ↗MedTech Dive

2022-11-29Signed collaboration agreement with Ethicon (Johnson & Johnson MedTech) to sell Versius in select hospitals in Italy, France, Germany and BrazilCMR Surgical